BOSTON and LAUSANNE,
Switzerland and BORDEAUX,
France and MARSEILLE, France, Feb.
1, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),
a leader in Data-Driven Medicine, have announced, in conjunction
with Assises de Génétique, an extension of their partnership with
Institut Paoli Calmettes (IPC), one of the 18 French Cancer
Comprehensive Centers (CLCC), to further support the
implementation, automatization, and accreditation of solid tumor
tests, to include lung, breast, ovarian and onco-hematological
cancers.
Recently named a Reference Medical Biology Laboratory, the
oncogenetic laboratory of Institut Paoli Calmettes manages
hereditary cancers and both solid tumor and myeloid/lymphoid
hematologic malignancies. IPC employs 1,800 research, medical, and
non-medical personnel with the goal of providing comprehensive care
for every aspect of cancer treatment, including research,
education, training, and medical and supportive care.
Today's announcement further builds on the partnership that
began between the two organizations in 2016, when IPC saw a need
for CNV analysis and implemented SOPHiA GENETICS' Hereditary Cancer
Solution. The partnership has since evolved with SOPHiA GENETICS
offering IPC one automatized workflow to cover hereditary cancers,
solid tumors, and hematologic tests, as well as Set-Up Program
assistance.
For more than half a decade, IPC and SOPHiA GENETICS have forged
new ways to target genomic profiling to optimize the management of
solid tumors and the increasing number and variety of biomarkers,
reducing unnecessary sequencing costs and minimizing time needed
for variant interpretation and reporting. Moreover, IPC has
recently performed an R&D test alongside SOPHiA GENETICS to
assess the versatility, accuracy, and robustness of SOPHiA
GENETICS' new Genomic Instability Index (GII) algorithm on ovarian
samples in relation to SOPHiA GENETICS' Homologous Recombination
Deficiency (HRD) solution.
"We are excited to extend our partnership with Institut Paoli
Calmettes to further optimize their solid tumor management.
Together, our mission-driven approach unlocks the potential of
multimodal health data to accelerate their ability to diagnose
cancer patients and better predict the best course of treatment,"
said Dr. Jurgi Camblong, co-founder and CEO of SOPHiA
GENETICS.
"Molecular oncogenetics is a constantly evolving field that
requires the flexibility of medical biology laboratories to adapt
to rapidly changing clinical needs. Also, the simple
customer-supplier relationship must be replaced by real listening
with the consideration of the specific user constraints to provide
adapted services in a very short time," said the Oncogenetic Team
at Institut Paoli Calmettes. "Our long-standing collaboration with
SOPHiA GENETICS fits into this context. It has enabled us to
implement a wide range of genetic, germline, and tumor analyses
(solid tumors and hematological malignancies). The ability to use
their algorithm to search for genome instability, alone or in
addition to our custom-made tumor panel, is a new step in this
partnership, for better care of our ovarian cancer patients and
prospects for other pathologies."
To learn more about how SOPHiA GENETICS' data-driven insights
are improving diagnosis, treatment and drug development for
patients and the larger medical community, visit
www.sophiagenetics.com.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH)
is a healthcare technology company dedicated to establishing the
practice of data-driven medicine as the standard of care and for
life sciences research. It is the creator of the SOPHiA DDM™
Platform, a cloud-based SaaS platform capable of analyzing data and
generating insights from complex multimodal data sets and different
diagnostic modalities. The SOPHiA DDM™ Platform and related
solutions, products and services are currently used by more than
790 hospital, laboratory, and biopharma institutions globally. For
more information, visit SOPHiAGENETICS.COM, or connect on Twitter,
LinkedIn and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures, unless specified otherwise. The
information included in this press release is about products that
may or may not be available in different countries and, if
applicable, may or may not have received approval or market
clearance by a governmental regulatory body for different
indications for use. Please contact
support@sophiagenertics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This
press release contains statements that constitute forward-looking
statements. All statements other than statements of historical
facts contained in this press release, including statements
regarding our future results of operations and financial position,
business strategy, products and technology, as well as plans and
objectives of management for future operations, are forward-looking
statements. Forward-looking statements are based on our
management's beliefs and assumptions and on information currently
available to our management. Such statements are subject to risks
and uncertainties, and actual results may differ materially from
those expressed or implied in the forward-looking statements due to
various factors, including those described in our filings with the
U.S. Securities and Exchange Commission. No assurance can be given
that such future results will be achieved. Such forward-looking
statements contained in this document speak only as of the date of
this press release. We expressly disclaim any obligation or
undertaking to update these forward-looking statements contained in
this press release to reflect any change in our expectations or any
change in events, conditions, or circumstances on which such
statements are based unless required to do so by applicable law. No
representations or warranties (expressed or implied) are made about
the accuracy of any such forward-looking statements.
About Paoli-Calmettes Institute
Based in Marseilles,
Paoli-Calmettes Institute is the first cancer comprehensive centre
in region providing global care for cancer. It is a member of the
national federation Unicancer. The Institute has been licensed by
the HAS (the overall French health authority) at the highest level
in 2015. The Centre gathers 1,800 employees - researchers, medical
doctors, health and administrative staff – engaged in wide range of
activities on site: prevention, research, treatment and training.
IPC registered over 100,000 consultations and almost 11,000
new patients in 2020. In addition, over 400 researchers work in
close collaboration with the medical teams to offer the cutting
edge scientific advancements and the highest level treatments
against cancers. Further information:
www.institutpaolicalmettes.fr
View original content to download
multimedia:https://www.prnewswire.com/news-releases/institut-paoli-calmettes-extends-partnership-with-sophia-genetics-301472606.html
SOURCE SOPHiA GENETICS